Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

As Role of Kinase Inhibitors in Rheumatic Disease Treatment Expands, Experts Review Therapy’s Failures, Successes

Thomas R. Collins  |  Issue: October 2016  |  October 10, 2016

This shows the janus kinase 1 protein, which is part of the JAK-STAT signalling pathway and a drug target.

This shows the janus kinase 1 protein, which is part of the JAK-STAT signalling pathway and a drug target.
molekuul_be/shutterstock.com

LONDON—Kinase inhibitors’ profile in the world of rheumatic disease therapy is growing, and they are probably going to play an even larger and more central role as time goes on, experts said at the Annual Congress of the European League Against Rheumatism (EULAR) 2016.

But Gary S. Firestein, MD, director of the Clinical and Translational Research Institute at the University of California San Diego, said it’s important to learn from the recent past in kinase-inhibitor research and the failed attempts to develop some compounds, such as spleen tyrosine kinase (Syk) and p38 MAP kinase inhibitors.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

With fostamatinib, studied in OSKIRA-4, there was less efficacy seen in Phase 3 than in earlier phases, and it became clear that hypertension and liver toxicity were problems.1 MK8457 showed some efficacy, but was discontinued due to serious infections and mortality.

Plus, Dr. Firestein noted, neither one of those drugs appeared to be effective in patients who were inadequate responders to TNF inhibitors. That, he said, “probably tells us about, in part, how TNF inhibitors work.” It’s more likely in series with Syk-inhibitors, not in parallel.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Janus kinase (JAK) inhibitors, the class of drugs that inhibits enzymes that are important in the signaling involved in immunity, are now in wide development. Twenty are now in the pipeline, with varying selectivity. Tofacitinib works on JAK 1 and 3, and to a lesser extent, JAK2. Decernotinib is mainly a JAK3 inhibitor but has some activity on the other JAKs. Baricitinib is a JAK 1 and 2 inhibitor, and filgotinib inhibits JAK 1.

Because the inhibition profiles all vary, using JAK inhibitors presents a challenge, but also a chance for better tailoring to a particular disease, Dr. Firestein said.

“These are degrees of selectivity, and they are not absolute,” he said. “The selection of which target you use and what profile you want for a particular indication might depend on the pathogenesis of the disease.”

Developing JAK inhibitors and some of the newer kinase inhibitors, such as PI3 delta inhibitors and Bruton’s tyrosine kinase inhibitors, will be a balancing act between efficacy and toxicity, he said.

“If it’s so clean and so selective that it is ineffective, then it is not a particularly good therapy,” he said. “Toxicity can be managed. Lack of efficacy cannot.”

Tailored Treatment

Iain McInnes, MD, PhD, director of the Research Institute for Infection, Immunity and Inflammation at the University of Glasgow, described work being done at his center to gather immunological data that can be used to tailor treatment.

In the Scottish Early RA Collaboration, researchers have tried to recruit every new case of rheumatoid arthritis. The cohort now includes 1,200 people. One part of this project—the Scottish Nested Arthritis Progression Study (SNAP)—involves detailed immunological phenotyping of patients as they progress through their first year with the disease.

Peripheral blood samples are analyzed ex vivo and then are stimulated with a “cytokine cocktail.” Researchers are looking for clues that will give them an idea of who will respond and of the nature of the response to a given therapeutic. Some of this work has focused on the JAK-STAT pathway.

The data are not yet published, but researchers have measured levels of phosphorylated STAT (pSTAT) proteins and found that higher levels of some pSTATs at baseline across distinct cell subsets seem to be a sign that someone will respond to methotrexate, Dr. McInnes said.

“It’s actually very much a STAT signal, which is telling us about the capacity of somebody to respond to methotrexate,” he said. “There are detectable signals in circulating peripheral blood of people with rheumatoid arthritis with early disease.”

As the search continues for new RA therapies, personalization will loom large, he said. And because JAK-inhibitors can target multiple cytokine receptors at the same time, they will have the capacity to play a big part in this process.

‘If [a therapy is] so clean & so selective that it is ineffective, then it is not a particularly good therapy. Toxicity can be managed. Lack of efficacy cannot.’ —Dr. Firestein

“New medicines that we are going to make in rheumatology, particularly rheumatoid, are only going to fly if they actually deliver real added value,” Dr. McInnes said. “Because their [JAK-inhibitors’] targets are discernible, they are really very interesting targets for the personalization of therapeutics.”

Effects on Cartilage & Bone Damage

A challenge going forward in the development of kinase inhibitors is determining their effects on cartilage and bone damage, said Florian Meier, MD, a clinical research fellow in rheumatology and clinical immunology at the University of Giessen.

Data on radiographic progression from clinical trials so far have been limited, and what have been collected have, for the most part, not been evaluated or shared yet, he said. Results from animal studies don’t necessarily predict results in humans, Dr. Meier said.

“Phase 2 clinical trial program(s),” he said, “should include data on radiographic progression.”


Thomas R. Collins is a freelance medical writer based in Florida.

References

  1. Taylor PC, Genovese MC, Greenwood M, et al. OSKIRA-4: A phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2015 Dec;74(12):2123–2129.
  2. Genovese MC, Yang F, Ostergaard M, et al. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Clinical and MRI findings. Ann Rheum Dis. 2016 Apr 15.
  3. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 31;374(13):1243–1252.

Page: 1 2 3 | Multi-Page
Share: 

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:EULARfailurejanus kinase inhibitorkinase inhibitorResearchRheumatic DiseasesuccesstargettherapyTNF inhibitorTreatment

Related Articles

    ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise

    May 1, 2013

    Toxicity and appropriate targeting are challenges for small molecule researchers

    JAK Inhibitors: Are All Promises Fulfilled?

    July 22, 2022

    A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.

    Dr. Gary Firestein: Musician & Semi-Retired Surfer

    August 16, 2019

    Roughly 20 years ago, Gary S. Firestein, MD, was surfing at Cloudbreak, a sheltered reef nearly three miles south of Namotu Island in Fiji. With waves soaring as high as 20 feet, it’s either a surfer’s dream or nightmare, and ranked among the 10 most challenging waves anywhere on the planet. At the time, Dr….

    ACR/ARHP Annual Meeting 2012: Genes Not the Only Factor in Susceptibility to Rheumatoid Arthritis

    March 1, 2013

    Epigenetics, innate immunity, and environmental stresses such as smoking could have more influence than scientists once believed

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences